ni Ronalyn Seminiano Reonico | July 13, 2020
Nagsagawa ng eksperimentasyon ang Chulalongkorn research team ng Bangkok, Thailand kung saan gumamit ng unggoy sa Covid-19 vaccine at ayon sa resulta ay tagumpay ang naturang trial. Hinihintay pa ang approval ng FDA sa Setyembre ngayong taon upang maisagawa ang vaccine trial sa tao.
Ayon sa director ng Chulalongkorn vaccine research center na si Prof Kiat Ruxrungtham, ang Chula-Covid19 ay isang mRNA vaccine na na-produced gamit ang genetic material ng coronavirus na kapag nai-inject sa katawan, magiging proteins na kayang palakasin ang antibodies na lalaban sa virus.
Sa isinagawang eksperimentasyon sa National Primate Research Centre ng Chulalongkorn University, matapos ang dalawang linggong pag-inject ng Chula-Covid19 sa mga unggoy, ayon sa blood test results, tumaas nag level of immunity ng mga ito.
Saad ni Dr. Kiat, “Within the next week, we will select two vaccines which are slightly different in genetic parts to deliver to two production plants in foreign countries. The first plant will produce a vaccine biopsy, expected to be complete in early October. After that, we will ask the factory No. 2 to produce vaccine-coated fat parts around November 2020. Then we will proceed with injections in phase 1 and the next phases. We have prepared about 10,000 doses for the volunteers, for an estimated 5,000 people. If the test is successful, the vaccine would be ready for use in people around the third or fourth quarter of next year.
“If it is effective and safe on six people, another 15 volunteers will receive a 30mcg vaccine and another 15 people will receive 100mcg of vaccine. If it is effective, a further test will be conducted in almost the same amount as the first phase. If all of this is safe, the third test will be conducted for the next 75 volunteers, aged 61-80.”